What are the immunization and safety effects of the COVID-19 adenovirus vector Astrazenaca vaccine in irradiated patients in Thailand? radiation, covid-19, vaccine
Conditions
Interventions
Participants recieved AstraZeneca vaccine and were taken a blood sample 5 times
Health Services Research
RT CU aztrazeneca
Sponsors
King Chulalongkorn Memorial Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1) Age greater than or equal to 18 years 2) ECOG Performance status 0-2 3) Well-controlled underlying disease 4) Life expectancy 6 months or more 5) was diagnosed with a solid cancer or a tumor that requires radiation therapy or radiation in combination with chemotherapy drugs with at least 10 radiation plans 6) Voluntarily receive the Astrazeneca COVID-19 vaccine. 7) Voluntarily join the program with written consent.
Exclusion criteria
Exclusion criteria: 1) Immunodeficiency conditions such as HIV infection or congenital immunodeficiency syndrome 2) A history of COVID-19 infection or a nucleocapsid protein IgG antibodies test before the first dose of vaccination has a positive result indicating a natural infection. 3) There is a radiation plan for total body irradiation (TBI), total lymphoid irradiation (TLI), craniospinal irradiation (CSI). 4) Receive chemotherapy drugs taken before radiation within 4 weeks (induction or palliative chemotherapy). 5) have received radiation before (previous radiotherapy) 6) Pregnant women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| antibody for spike protein at 12 months after end of the study antispike antibody testing | — |
Secondary
| Measure | Time frame |
|---|---|
| antibody for spike protein at 12 months after end of the study antispike antibody testing | — |
Countries
Thailand
Contacts
Public ContactAnussara prayongrat
Ministry of Health
Outcome results
None listed